長尾 充展
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine
   Position   Associate Professor
Article types Original article
Language English
Peer review Peer reviewed
Title Quantification of myocardial iron deficiency in nonischemic heart failure by cardiac T2* magnetic resonance imaging.
Journal Formal name:The American journal of cardiology
Abbreviation:Am J Cardiol
ISSN code:(1879-1913)0002-9149(Linking)
Domestic / ForeginForegin
Volume, Issue, Page 113(6),pp.1024-30
Author and coauthor Nagao Michinobu, Matsuo Yoshio, Kamitani Takeshi, Yonezawa Masato, Yamasaki Yuzo, Kawanami Satoshi, Abe Kohtaro, Mukai Yasushi, Higo Taiki, Yabuuchi Hidetake, Takemura Atsushi, Yoshiura Takashi, Sunagawa Kenji, Honda Hiroshi
Authorship Lead author,Corresponding author
Publication date 2014/03
Summary The aim of this study was to use T2* cardiac magnetic resonance (CMR) imaging to quantify myocardial iron content in patients with heart failure (HF) and to investigate the relation between iron content, cardiac function, and the cause of HF. CMR data were analyzed from 167 patients with nonischemic and 31 with ischemic HF and 50 patients with normal ventricular function. Short-axis T2* imaging was accomplished using 3-T scanner and multiecho gradient-echo sequence. Myocardial T2* value (M-T2*) was calculated by fitting the signal intensity data for the mid-left ventricular (LV) septum to a decay curve. Patients with nonischemic HF were categorized into patients with LV ejection fraction (LVEF) <35% or ≥35%. The relation between nonischemic HF with LVEF <35% and the risk for major adverse cardiac events was analyzed by multivariate logistic regression analysis using M-T2* and HF biomarkers. M-T2* was significantly greater for patients with nonischemic HF (LVEF <35%: 29 ± 7 ms, LVEF ≥35%: 26 ± 5 ms) than for patients with normal LV function (22 ± 3 ms, p <0.0001) or ischemic HF (22 ± 4 ms, p <0.001). The odds ratio was 1.21 for M-T2* (p <0.0001) and 1.0015 for brain natriuretic peptide (p <0.0001) in relation to nonischemic HF with LVEF <35%. Furthermore, this value was 0.96 for systolic blood pressure (p = 0.012) and 1.02 for M-T2* (p = 0.03) in relation to the risk for major adverse cardiac events in patients with nonischemic HF. In conclusion, T2* CMR demonstrated the robust relation between myocardial iron deficiency and nonischemic HF. M-T2* is a biomarker that can predict adverse cardiac function in patients with nonischemic HF.
DOI 10.1016/j.amjcard.2013.11.061
PMID 24461766